The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Discuss whatever you want here ... movies, books, recipes, politics, beer, wine, TV ... everything except classical music.

Moderators: Lance, Corlyss_D

Post Reply
maestrob
Posts: 10126
Joined: Tue Sep 16, 2008 11:30 am

The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by maestrob » Fri Apr 02, 2021 10:09 am

Britain reported 30 cases of extremely rare blood clots in people who had received the AstraZeneca-Oxford vaccine, the same sort of events that have prompted some European countries to restrict use of the shot in certain at-risk age groups.

The reports represented 25 more cases than Britain’s medicines regulator had previously received, going some way toward addressing a mystery that has hung over safety concerns about the vaccine: why Britain had not observed the same phenomenon that has been seen in continental Europe, driving countries including France, Germany and Sweden to stop giving the shot to younger people, who are believed to be at higher risk from the rare clotting events.

Britain’s medicines regulator said that it had received reports of no such clotting cases in people who had received the Pfizer-BioNTech vaccine.

The clotting cases have generated concern because, scientists said, they were somewhat unusual. They involve blood clots combined with unusually low levels of platelets, a disorder that can lead to heavy bleeding.

The clotting events that have drawn the most concern, known as cerebral venous sinus thrombosis, entail clots in the veins that drain blood from the brain, a condition that can lead to a rare type of stroke. Those represented 22 of the 30 clotting cases that Britain reported this week.

But it is not clear whether any of the cases are linked to the vaccine. And even if they are, British and European regulators have said they were so rare that the vaccine should continue to be used.

On Thursday, Germany’s immunization commission, the STIKO, recommended that anyone younger than 60 who received an initial vaccination with AstraZeneca be given either Pfizer-BioNTech or Moderna shots as their second vaccine doses.

In reporting its updated case count, Britain’s medicines regulator said that “the benefits of the vaccines against Covid-19 continue to outweigh any risks, and you should continue to get your vaccine when invited to do so.” The European Union’s medicines regulator has also recommended that countries continue to use the AstraZeneca vaccine. Both agencies are continuing to investigate.

Scientists said on Friday that the overall risk of the particular clotting events that have drawn concern was extremely low: roughly one case in 600,000 recipients of the AstraZeneca vaccine in Britain. And it is difficult to know how common the cases are in the general population, given that it can be hard to diagnose. Scientists have said that case counts would inevitably rise among vaccinated people as doctors began looking more closely for the condition.

David Werring, a professor at University College London’s Institute of Neurology, said that the unusual presentation of the cases in vaccinated people was creating concern about possible links with the shot.

But, he said, “The key thing to remember is how rare these brain clots are, and how powerful the proven benefit of vaccination is against Covid.” He added that doctors and people who had received the AstraZeneca vaccine should be on the lookout for symptoms of the clotting events, like severe headaches or signs of a stroke.

“More research is urgently needed,” he said.

Melissa Eddy contributed reporting.

— Benjamin Mueller

https://www.nytimes.com/live/2021/04/02 ... irus-cases

Holden Fourth
Posts: 1608
Joined: Fri Mar 25, 2005 5:47 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by Holden Fourth » Fri Apr 02, 2021 8:08 pm

maestrob wrote:
Fri Apr 02, 2021 10:09 am
Britain reported 30 cases of extremely rare blood clots in people who had received the AstraZeneca-Oxford vaccine, the same sort of events that have prompted some European countries to restrict use of the shot in certain at-risk age groups.

The reports represented 25 more cases than Britain’s medicines regulator had previously received, going some way toward addressing a mystery that has hung over safety concerns about the vaccine: why Britain had not observed the same phenomenon that has been seen in continental Europe, driving countries including France, Germany and Sweden to stop giving the shot to younger people, who are believed to be at higher risk from the rare clotting events.

Britain’s medicines regulator said that it had received reports of no such clotting cases in people who had received the Pfizer-BioNTech vaccine.

The clotting cases have generated concern because, scientists said, they were somewhat unusual. They involve blood clots combined with unusually low levels of platelets, a disorder that can lead to heavy bleeding.

The clotting events that have drawn the most concern, known as cerebral venous sinus thrombosis, entail clots in the veins that drain blood from the brain, a condition that can lead to a rare type of stroke. Those represented 22 of the 30 clotting cases that Britain reported this week.

But it is not clear whether any of the cases are linked to the vaccine. And even if they are, British and European regulators have said they were so rare that the vaccine should continue to be used.

On Thursday, Germany’s immunization commission, the STIKO, recommended that anyone younger than 60 who received an initial vaccination with AstraZeneca be given either Pfizer-BioNTech or Moderna shots as their second vaccine doses.

In reporting its updated case count, Britain’s medicines regulator said that “the benefits of the vaccines against Covid-19 continue to outweigh any risks, and you should continue to get your vaccine when invited to do so.” The European Union’s medicines regulator has also recommended that countries continue to use the AstraZeneca vaccine. Both agencies are continuing to investigate.

Scientists said on Friday that the overall risk of the particular clotting events that have drawn concern was extremely low: roughly one case in 600,000 recipients of the AstraZeneca vaccine in Britain. And it is difficult to know how common the cases are in the general population, given that it can be hard to diagnose. Scientists have said that case counts would inevitably rise among vaccinated people as doctors began looking more closely for the condition.

David Werring, a professor at University College London’s Institute of Neurology, said that the unusual presentation of the cases in vaccinated people was creating concern about possible links with the shot.

But, he said, “The key thing to remember is how rare these brain clots are, and how powerful the proven benefit of vaccination is against Covid.” He added that doctors and people who had received the AstraZeneca vaccine should be on the lookout for symptoms of the clotting events, like severe headaches or signs of a stroke.

“More research is urgently needed,” he said.

Melissa Eddy contributed reporting.

— Benjamin Mueller

https://www.nytimes.com/live/2021/04/02 ... irus-cases
The part of the article I bolded and put in italics is once again an example of fearmongering on the part of our media. "It isn't proved but we'll print it anyway". The worrying thing is that this will cause even more people to refuse the jab which can't be good if we want to make the pandemic, endemic. I simply see this as irresponsible journalism.

maestrob
Posts: 10126
Joined: Tue Sep 16, 2008 11:30 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by maestrob » Sat Apr 03, 2021 7:45 am

Interesting that you should see it that way.

So you would rather that things should be hidden from the public? Really??

I find that withholding information is a terrible idea. The article makes clear that there has been no established link of these deaths to the vaccine, yet this kind of incident has not taken place with the other brands, which I certainly believe is information that the public should have. Let people know the reality of the situation and make their own decisions.

Nothing irresponsible here at all. Just because it's the N. Y. Times, you want to attack their reporting, is that it? :mrgreen:

Holden Fourth
Posts: 1608
Joined: Fri Mar 25, 2005 5:47 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by Holden Fourth » Sat Apr 03, 2021 7:53 pm

Nothing to do with the NYT and everything to do with balanced reporting. For example, not mentioned was the number of vaccinations already carried out in the UK as a fraction of the number of blood clot issues. There are probably other allergic reactions to any of the covid shots as there are with any medication and that hasn't been mentioned either. I could go on and I'm not singling out the NYT - this has been reported like this in other media outlets.

barney
Posts: 5440
Joined: Fri Aug 01, 2008 11:12 pm
Location: Melbourne, Australia

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by barney » Sat Apr 03, 2021 8:50 pm

But surely the part you bolded WAS responsible journalism, saying exactly what you think should be said?

Holden Fourth
Posts: 1608
Joined: Fri Mar 25, 2005 5:47 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by Holden Fourth » Mon Apr 05, 2021 7:09 pm

barney wrote:
Sat Apr 03, 2021 8:50 pm
But surely the part you bolded WAS responsible journalism, saying exactly what you think should be said?
Exactly which is why I put it in bold. Here is something from the SMH yesterday which takes a much more two sided approach.

By Liam Mannix
April 5, 2021 — 7.45pm

The Thrombosis and Haemostasis Society Australia and New Zealand, the country’s acting chief medical officer and the medical regulator, do not believe there is hard evidence yet of a link between AstraZeneca’s COVID-19 vaccine and a rare blood clotting syndrome.

A 44-year-old man who received the AstraZeneca vaccine remains in Melbourne’s Box Hill Hospital with a probable case of the rare syndrome, termed suspected vaccine induced prothrombotic immune thrombocytopenia (VIPIT).
A Melbourne man has developed a blood clot after taking the AstraZeneca vaccine.

We cannot say there is a causal link. That’s the bottom line,” said Associate Professor Vivien Chen, lead author of the Thrombosis and Haemostasis Society’s just-released guidance on VIPIT. “This is a new, emerging syndrome. The scientific investigations to show causality have not been done.”

However, Professor Jim Buttery, head of epidemiology and signal detection at the Victorian immunisation safety service, said he now believed there was evidence of a link.

“Although not conclusively proven yet, it is likely there is a causal link between the AstraZeneca vaccine and this rare subset of thrombosis with thrombocytopenia,” he told The Age via email.

“Based on the data available to date at the moment it appears the UK detected 30 cases from 18 million doses of vaccine, approximately 1 in 500,000 doses.”

Available evidence suggests the syndrome is extremely rare. Norway has reported a rate of 1 in every 25,000 doses, Germany has reported a rate of 1 in 100,000, while Europe’s overall figures are 1 in 210,000. Britain has recorded a much lower rate: 30 reported cases from 18.1 million AstraZeneca injections – around 1 in 500,000.

In comparison, a 65-year-old has between a 1 or 2 in 100 chance of dying if infected with COVID-19, with that risk continuing to rise with age.

The European Medicines Agency and Australia’s Therapeutic Goods Administration say the benefits of the vaccine continue to outweigh any risks.
Related Article
Doses of the AstraZeneca COVID-19 vaccine are seen at the Boigu community centre on March 24, 2021 in Boigu Island, Australia. COVID-19 vaccinations have started ahead of schedule in the Torres Strait, with health authorities bringing forward the coronavirus vaccine rollout amid growing concerns of an outbreak in the remote region as nearby Papua New Guinea grapples with a COVID-19 epidemic.
Coronavirus pandemic
Concerns that AstraZeneca clotting case may hurt public confidence in vaccine

Initially, much of the focus was whether AstraZeneca’s vaccine may raise the overall risk of blood clots. There is now evidence to show this is not the case. However, that concern turned out to be something of a red herring.

Our blood is filled with platelet cells, which are able to clot together when we are bleeding and clog the wound. This is why you stop bleeding soon after cutting yourself.

Cases of VIPIT are characterised by four things: low levels of platelets, high levels of blood clotting breakdown products, the formation of blood clots, and the presence of a specific antibody that over-activates platelets in the blood.

“It’s predominantly blood clots in what we would call unusual places,” said Dr Chen.

The unusual antibodies are a hallmark of the syndrome. They activate the platelets, which has the dual effect of causing blood clots to form while also removing other platelets from the bloodstream.

“There are several mechanisms by which the antibodies could develop , and as yet we don’t know the exact mechanism,” said Professor Paul Monagle, a paediatric haematologist at the University of Melbourne who is studying the syndrome.

“One possibility is it is creating antibodies, and those antibodies are recognising some sequence on the platelets, instead of the vaccine.”

Potential risk factors also remain unclear. Most of the cases reported so far were in women younger than 55.

That has led several European countries to stop giving AstraZeneca to people aged under 60. However, it could be that age and gender are not risk factors. Many European countries gave AstraZeneca to younger groups first, as well as healthcare workers – of which a large proportion are women.

Liam Mannix

In the article I've bolded one statement and put another in italics. They reflect opposing views and what I applaud Liam Mannix for is how he has put them on the same part of the article. This gives me, the reader, the chance to see that there are two points of view and I am free, right or wrong, to make up my own mind. As a journo Barney, surely this is what you would like to see? When I compare this to the NYT article and one from the UK it's like a breath of fresh air.

Finally, Mr Mannix didn't treat me, the reader, like I was a 12 year old with limited discernment. I learnt a lot about this syndrome from his SMH piece.

maestrob
Posts: 10126
Joined: Tue Sep 16, 2008 11:30 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by maestrob » Tue Apr 06, 2021 8:10 am

G'day, Holden.

Your article does provide more information, including the speculation that there probably is a causal link. The N. Y. Times wisely (I think) decided not to include that bit of information (perhaps because America is now populated by too many anti-vaxxers who would seize on this?), as nothing has yet been proven.

Although I'm certainly not a scientist, I am indeed concerned that this syndrome of blood clotting has only turned up in people who have had the Astra-Zeneca vaccine, however rare such incidents may be. I'm also thankful that our approval process has held up the distribution of that vaccine in the United States. Given that company's flawed and hasty reporting of their trial data, and now this latest problem, I have my doubts that it will be offered here.

I also think that the EU acted hastily in approving the A-Z vaccine for use there, and that they continue to urge people to take it astounds me.

If I were in your shoes, I certainly would not take it. Innocent until proven guilty may work in the courtroom, but that's not good enough for something that I'm Injecting into my body, especially when other brands are available without any such baggage.

maestrob
Posts: 10126
Joined: Tue Sep 16, 2008 11:30 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by maestrob » Tue Apr 06, 2021 9:35 am

A vaccine official says there is a link between AstraZeneca’s shot and rare blood clots.

A top vaccines official at the European Medicines Agency said on Tuesday that AstraZeneca’s vaccine was linked to blood clots in a small number of recipients, the first indication from a leading regulatory body that the clots may be a real, if extremely rare, side effect of the shot.

The agency itself has not formally changed its guidance, issued last week, that the benefits of the AstraZeneca vaccine outweigh the risks. It said on Tuesday that its review was ongoing and that it would announce its findings this week. But any further ruling from regulators would be a setback for a shot that Europe and much of the world are relying on to save lives amid a global surge in coronavirus cases.

The medicines agency said last week that no causal link between the vaccine and rare blood clots had been proven. Only a few dozen cases of blood clots have been recorded among the many millions of people who have received the vaccine across Europe.

But the vaccines official, Marco Cavaleri, told an Italian newspaper that “it is clear there is an association with the vaccine.” He said that it would likely remain up to individual countries to decide how to respond, given the variation in supply of Covid-19 vaccines and in the state of the virus.

Those comments represented the first indication from a member of a leading regulatory body that the blood clots could be a genuine, if extremely rare, side effect of the AstraZeneca vaccine. Previously, health officials in several European countries temporarily restricted the use of the shot in certain age groups, despite the European Medicines Agency’s recommendation to keep administering it.

Regulators in Britain and at the World Health Organization have also said that, while they were investigating any rare side effects, the shot was safe to use and would save many lives.

Mr. Cavaleri told the Italian newspaper Il Messaggero that European regulators had not determined why the vaccine might be causing the rare blood clots, which generated concern because the cases were so unusual. They involved blood clots combined with unusually low levels of platelets, a disorder that can lead to heavy bleeding.

The most worrisome of the conditions, known as cerebral venous sinus thrombosis, involves clots in the veins that drain blood from the brain, a condition that can lead to a rare type of stroke.

The clots are, by all accounts, extremely rare. European regulators were analyzing 44 cases of cerebral venous sinus thrombosis, 14 of them fatal, among 9.2 million people who received the AstraZeneca vaccine across the continent. Emer Cooke, the European Medicines Agency’s director, said that the clotting cases in younger people translated to a risk for one in every 100,000 people under 60 given the vaccine. Younger people, and especially younger women, are at higher risk from the brain clots, scientists have said.

In Britain, regulators last week reported 30 cases of the rare blood clots combined with low platelets among 18 million people given the AstraZeneca vaccine, which was developed with the University of Oxford. No such cases were reported in people who had received the Pfizer-BioNTech vaccine in Britain.

Regulators in Britain have said that people should get the vaccine “when invited to do so.” But British news reports indicated Monday night that regulators were considering updating that guidance for certain age groups.

Monika Pronczuk and Emma Bubola contributed reporting.

— Benjamin Mueller

https://www.nytimes.com/live/2021/04/06 ... irus-cases

maestrob
Posts: 10126
Joined: Tue Sep 16, 2008 11:30 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by maestrob » Wed Apr 07, 2021 10:42 am

U.K. says AstraZeneca alternative should be offered for under 30s, and E.U. finds a ‘possible link’ to rare clots.

Britain said on Wednesday that it would offer alternatives to the AstraZeneca vaccine for adults under 30 as European regulators described a “possible link” with rare blood clots, a setback for the world’s most widely used vaccine and a blow to the more than 100 countries relying on it to save lives amid a global surge in coronavirus cases.

The European regulator, the European Medicines Agency, stopped short of advising that use of the vaccine be curbed in the 27 European Union countries, saying that it was up to the national authorities to decide who should receive which vaccine.

Until the announcement, Britain had never wavered in its use of the vaccine, making it a holdout in Europe even as many countries detected unusual, sometimes fatal, blood clots in some recipients. But evidence has mounted that very small numbers of Britons had also been afflicted, forcing the country to reduce the use in younger people of a vaccine that is the backbone of its world-beating inoculation program.

The concern over the blood clots has threatened the pace of vaccinations far beyond Europe. At least 111 countries of varying income levels have administered doses of AstraZeneca’s shot, making it international aid groups’ most potent weapon in the battle to reduce deaths in the vaccine-starved global south.

British and European regulators both said it was possible that the clots were linked to the vaccine, but that more investigation was needed. European regulators described the cases as a serious but “very rare” side effect.

The agency reiterated that the overall benefits of the vaccine still outweighed the risks, but urged that health professionals and recipients of the shot be cautious about symptoms like shortness of breath, chest pain or leg swelling.

Many European countries have restricted use of the vaccine in younger people because some scientists believe they are at higher risk of developing the rare blood clots. They are also at lower risk of severe Covid-19, raising the safety bar for any vaccine being given to younger people.

But the regulator said that it had not concluded that age or gender were a specific risk and that it would further investigate the issue.

“This case clearly demonstrates one of the challenges posed by large scale vaccination campaigns,” Emer Cooke, the agency’s head, said in a news conference on Wednesday. “When millions of people receive these vaccines, very rare events can occur that were not identified during the clinical trials.”

No other vaccine has stirred as much controversy as the shot made by the British-Swedish company, setting off spats with the bloc over cuts in supply, its efficacy and finally over rare, but sometimes fatal, blood clots reported in some recipients.

Those concerns led several European countries to first restrict the use of AstraZeneca in older age groups, then suspend it over reports of blood clots, only to roll it out again last month after the European Medicines Agency issued a preliminary opinion that the benefits of the vaccine outweighed the risks.

As doctors reported a higher incidence of serious blood clots in younger people, some countries decided to stop administering the shot to anyone younger than 55.

Europe’s concerns over the vaccine’s side effects are also likely to threaten global inoculation efforts, with much of the developing world depending on the AstraZeneca vaccine to tackle the pandemic. The shot is the cornerstone of Covax, a program designed to make vaccine access more equitable worldwide.

The vaccine appeared to be causing an immune reaction in which antibodies bind to platelets, activating them, German doctors and the European Medicines Agency have said. Those platelets, in turn, were causing the formation of dangerous clots in certain parts of the body, including in veins that drain blood from the brain, leading in some cases to a rare type of stroke.

Why the antibodies develop in these people is not known, doctors have said. Some component of the vaccine, or excessive immune reaction — or both — could be the cause, they said.

No pre-existing conditions are known to make patients more vulnerable to this clotting disorder after a vaccination, European regulators said.

— Benjamin Mueller, Monika Pronczuk and Matina Stevis-Gridneff

https://www.nytimes.com/live/2021/04/07 ... irus-cases

Holden Fourth
Posts: 1608
Joined: Fri Mar 25, 2005 5:47 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by Holden Fourth » Wed Apr 07, 2021 8:49 pm

...and possibly looking to the future......

https://www.news.com.au/technology/inno ... bc24cfe4fa

Let's hope that work and human trials occur once again. I like the idea of having control of something that we've developed ourselves.

maestrob
Posts: 10126
Joined: Tue Sep 16, 2008 11:30 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by maestrob » Thu Apr 08, 2021 8:08 am

Holden Fourth wrote:
Wed Apr 07, 2021 8:49 pm
...and possibly looking to the future......

https://www.news.com.au/technology/inno ... bc24cfe4fa

Let's hope that work and human trials occur once again. I like the idea of having control of something that we've developed ourselves.
I'd say that looks promising indeed. I really don't like that EU and British regulators are still recommending Astra-Zeneca's shot, as are the authorities in Australia. If I were living in a country with such low infection rates, I'd be very hesitant about having the A-Z shot.

Since the Pfizer vaccine is authorized for use there, I'd insist on having that one at this point.

maestrob
Posts: 10126
Joined: Tue Sep 16, 2008 11:30 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by maestrob » Thu Apr 08, 2021 9:08 am

More countries pause AstraZeneca vaccine use amid warnings on rare blood clots.

A day after European regulators described a “possible link” between AstraZeneca’s Covid-19 vaccine and rare blood clots, the drug faced increasing hurdles on Thursday as countries around the world move to restrict its use in younger people. The decisions are the latest setback for AstraZeneca, the world’s most widely used coronavirus vaccine.

Although European regulators said that the vaccine’s benefits outweighed the risks for most people, several countries are now using the AstraZeneca shot only on older people who are most at risk of dying from the coronavirus. The Philippines said that it would temporarily stop administering the vaccine to people age 60 and under.

South Korean officials said that they would decide this weekend whether to resume administering the shot to people 60 and younger after a panel of experts reviewed the information on blood clots on Thursday.

Late Wednesday, Belgium said that it would temporarily halt use of the vaccine in people under 56, and that younger people will be offered alternative vaccines — measures that the country’s health ministry said would be reviewed in four weeks. Others, including Cameroon, the Democratic Republic of Congo, Denmark and Norway, have suspended use of the vaccine altogether until more information about the clotting risk is available.

Prime Minister Scott Morrison of Australia said at a news conference late Thursday that the country had changed its guidance on the AstraZeneca vaccine for younger people out of an abundance of caution. It now recommends that adults under 50 be given an alternative vaccine.

“We expect that this will require some changes to the arrangements we have as part of the vaccination rollout,” Mr. Morrison said during the briefing. Public health experts and the prime minister were clear that the decision was based on weighing the very low risks of complications from the vaccine against the risk of the coronavirus.

“Our purpose here tonight is to reassure Australians — to reassure them that we’ve been very clear about what the very low level of risk is here,” Mr. Morrison said.

In the Philippines, Rolando Enrique Domingo, the director general of the country’s Food and Drug Administration, said that there had been no local reports of blood clots, but that the government was taking a precautionary step after the European Medicines Agency’s decision to list clots as a rare side effect of the AstraZeneca vaccine.

In the meantime, he said, inoculations using the Chinese-produced Sinovac vaccine will continue.

“We await results of the review being done by our local experts, as well as the official guidance of the W.H.O.,” Mr. Domingo said, referring to the World Health Organization.

— Jason Gutierrez, Monika Pronczuk and Megan Specia

https://www.nytimes.com/live/2021/04/08 ... irus-cases

Holden Fourth
Posts: 1608
Joined: Fri Mar 25, 2005 5:47 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by Holden Fourth » Thu Apr 08, 2021 4:07 pm

...and this from the only media publication I read on a daily basis.

THE SQUIZ

Just as Australia hits the 1 million mark of COVID vaccines administered, PM Scott Morrison last night fronted the media to say he'd received advice that adults aged under 50yo who have not already received their first dose of AstraZeneca vaccine should be given the Pfizer vaccine going forward. The AstraZeneca vaccine should only be given to those aged under 50yo where the benefit of being immunised against the coronavirus "clearly outweighs the risk for that individual's circumstances." It's not a directive, he said, but it's what the government’s expert vaccine advisory body has recommended.

THIS IS ABOUT THE RISK OF BLOOD CLOTS?

Yep. Yesterday, the European Medicines Agency said there is the possibility of patients developing very rare cases of blood clots within two weeks of vaccination with the AstraZeneca jab, and our government tasked its official advisers to look at it. There have been reports of a slightly higher incidence of clots reported in younger adult age groups in the range of 4-6 cases per million vaccine recipients. "To put that in some sort of perspective, the combined oral contraceptive pill - that can include adverse side effects [of blood clots] - that's 7-to-10 per 10,000." But the cases of blood clots after receiving the AstraZeneca vaccine have shown a 25% death rate, and advice from the Aussie experts is to target its rollout to those aged 50yo and over.

SO WHAT DOES THAT MEAN FOR GETTING AUSSIES VACCINATED?

Good question - and watch this space… Last night, Morrison said there will "be a recalibration" to "take into account the decision the government has taken tonight" - but it looks like plans to have all willing Aussie receive at least one dose of a vaccine by October are dashed. The Pfizer-produced vaccine is in circulation, and there will need to be a process of “prioritisation”, and the government will now have to “work through the logistics of that," Morrison said. Which is a good time to note that Australia has done deals with 4 vaccine producers for almost 150 million doses at the cost of $3.3 billion - and the AstraZeneca vaccine makes up 53.8 million of those. Labor leader Anthony Albanese yesterday said that the episode has shown “the Federal Government should have secured more deals” with other vaccine producers. The National Cabinet is meeting today where this will be the top agenda item.

I guess this will push me well and truly up the list for getting vaccinated depending on what Cabinet decide today. Not that I'm bothered either way, I'll just have it when it's available to me

barney
Posts: 5440
Joined: Fri Aug 01, 2008 11:12 pm
Location: Melbourne, Australia

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by barney » Thu Apr 08, 2021 6:38 pm

maestrob wrote:
Thu Apr 08, 2021 8:08 am
Holden Fourth wrote:
Wed Apr 07, 2021 8:49 pm
...and possibly looking to the future......

https://www.news.com.au/technology/inno ... bc24cfe4fa

Let's hope that work and human trials occur once again. I like the idea of having control of something that we've developed ourselves.
I'd say that looks promising indeed. I really don't like that EU and British regulators are still recommending Astra-Zeneca's shot, as are the authorities in Australia. If I were living in a country with such low infection rates, I'd be very hesitant about having the A-Z shot.

Since the Pfizer vaccine is authorized for use there, I'd insist on having that one at this point.
I'd like to Brian, but it would mean waiting till 2027 to get a vaccine. The Government has really mucked this one up.

Holden Fourth
Posts: 1608
Joined: Fri Mar 25, 2005 5:47 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by Holden Fourth » Thu Apr 08, 2021 9:42 pm

Priority should be given to those most important - the front line workers including

Top of the list:

border control
emergency services
MIQ staff -that's anyone who works in the building at any point
Vaccine distributors
all medical staff including doctors, nurses, dentists, hospital employees, etc, etc.
Airline staff involved in any way with the possibility of coming in contact with infected people

It's only then we look at the vulnerable such as our fragile elderly and those with comorbidities.

I don't appear anywhere there and am happy to wait. We've got a chance to get it right this time.

barney
Posts: 5440
Joined: Fri Aug 01, 2008 11:12 pm
Location: Melbourne, Australia

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by barney » Fri Apr 09, 2021 4:03 am

Well, we don't seem to be going so well so far. Lucky we are an island and can keep out all those pesky people who want to come and bring Covid with them.

maestrob
Posts: 10126
Joined: Tue Sep 16, 2008 11:30 am

Re: The U.K. reports more blood-clotting cases in people who received the AstraZeneca shot.

Post by maestrob » Fri Apr 09, 2021 8:51 am

barney wrote:
Fri Apr 09, 2021 4:03 am
Well, we don't seem to be going so well so far. Lucky we are an island and can keep out all those pesky people who want to come and bring Covid with them.
The one positive takeaway from all this is that we seniors seem not to develop blood clots the way youngsters do, thus the EU has decided to stop using the vaccine in those under 55-60, while England has limited its use to those under 30. The problem seems to occur more often in women than in men.

https://www.theguardian.com/society/202 ... -regulator

Post Reply

Who is online

Users browsing this forum: No registered users and 49 guests